01—Abstract
Summary
Summary of the 10-K filed February 13, 2012. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation reported robust revenue growth in 2011, driven by strong performance across its three key segments: Reconstructive, MedSurg, and Neurotechnology and Spine.
The company's strategic acquisitions, particularly the significant Neurovascular division acquisition from Boston Scientific, played a crucial role in expanding its market presence and product portfolio, especially in the neurotechnology space. Despite a challenging economic environment and increased R&D investments, Stryker demonstrated solid operational execution, with notable revenue increases in both domestic and international markets.
The company also managed its costs effectively, although certain one-time charges related to restructuring and acquisition integration impacted reported net earnings. Stryker's financial position remains strong, supported by healthy operating cash flow and a well-managed debt structure, allowing for continued investment in innovation and shareholder returns through dividends and share repurchases.
02—Key points
Key Highlights
- Stryker Corporation generated $8,307 million in net sales in 2011, a 13.5% increase year-over-year, with constant currency sales growth of 11.1%.
- The company completed several strategic acquisitions in 2011, including the significant Neurovascular division from Boston Scientific for $1,450 million, bolstering its Neurotechnology and Spine segment.
- The Neurotechnology and Spine segment experienced substantial growth, with net sales increasing by 48.5% (46.4% in constant currency) due to acquisitions.
- Operating income for 2011 was $1,686 million, a slight decrease from $1,751 million in 2010, impacted by increased operating expenses including R&D and SG&A.
- Net earnings for 2011 were $1,345 million, an increase of 5.7% from 2010, with diluted EPS of $3.45.
- The company repurchased 11.8 million shares of common stock in 2011 for a total cost of $622 million, demonstrating a commitment to returning capital to shareholders.
- Research, development, and engineering expenses increased by 17.3% in 2011, reflecting a strategic focus on new product development and innovation.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Stryker Corp kept $0.16.
- Revenue$8.31B100.0%
- Cost of revenue−$2.81B33.8%
- Gross profit$5.50B66.2%
- Operating costs−$3.81B45.9%
- Operating income$1.69B20.3%
- Interest, other & tax−$341.0M4.1%
- Net income$1.34B16.2%
Where FY2011 revenue went
$8.31B- SG&A: $3.15B, 38% of revenue
- Cost of revenue: $2.81B, 34% of revenue
- Net income: $1.34B, 16% of revenue
- R&D: $462.0M, 5.6% of revenue
- Other operating costs: $198.0M, 2.4% of revenue
- Interest, other & tax: $341.0M, 4.1% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 13, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $8.31B$7.32B | +13.5% |
| Cost of Revenue | $2.81B$2.29B | +23.0% |
| Gross Profit | $5.50B$5.03B | +9.2% |
| R&D Expenses | $462.00M$394.00M | +17.3% |
| SG&A Expenses | $3.15B$2.71B | +16.4% |
| Operating Expenses | $3.81B$3.28B | +16.1% |
| Operating Income | $1.69B$1.75B | −3.7% |
| Interest Expense | $56.00M$53.00M | +5.7% |
| Net Income | $1.34B$1.27B | +5.7% |
| EPS (Basic) | $3.48$3.21 | +8.4% |
| EPS (Diluted) | $3.45$3.19 | +8.2% |
| Shares Outstanding (Basic) | 386.50M396.40M | −2.5% |
| Shares Outstanding (Diluted) | 389.50M399.50M | −2.5% |
05—Questions
Frequently Asked Questions
What were the main drivers of Stryker's revenue growth in 2011?
Stryker's revenue growth in 2011 was primarily driven by increased unit volume and favorable changes in product mix across its Reconstructive and MedSurg segments, alongside significant contributions from strategic acquisitions, particularly in the Neurotechnology and Spine segment. International sales also saw substantial growth, especially in constant currency.
How did the acquisitions in 2011 impact Stryker's financial results?
The acquisitions completed in 2011, most notably the Neurovascular division, significantly boosted revenue, especially within the Neurotechnology and Spine segment. These acquisitions contributed $496 million or 6.8% to net sales in 2011. However, they also led to increased acquisition and integration-related charges, including a $143 million cost related to the fair value step-up of acquired inventory, which impacted profitability.
What are the key risks highlighted by Stryker in its 2011 10-K filing?
Key risks identified include intense competition in the medical technology industry, dependence on intellectual property protection, stringent governmental regulations, healthcare cost containment measures leading to pricing pressures, potential product liability claims, challenges in maintaining relationships with healthcare professionals, risks associated with extensive international operations (including currency fluctuations), and the potential impact of macroeconomic developments.
What is Stryker's financial position and liquidity outlook?
Stryker maintained a strong financial position with $3,418 million in cash and marketable securities at the end of 2011. The company generated solid operating cash flow of $1,434 million. Liquidity is supported by ongoing operations and a $1,000 million credit facility. The company anticipates continued ability to support its liquidity needs through operations and potentially capital markets, with strong debt ratings.
06—Continue